Histidine

Histidine

SCHEMBL305855

NC(Cc1c[nH]cn1)C(=O)O.NCCCCC(N)C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.54
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
ARG1 P05089 4/20 0.40
CPB2 Q96IY4 3/20 0.40
CPB1 P15086 1/20 0.40
CYP3A4 P08684 1/20 0.38
SLC7A5 Q01650 1/20 0.38
THRB P10828 1/20 0.38
CYP1A2 P05177 1/20 0.38
MMP2 P08253 1/20 0.37
ARG2 P78540 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL28245493 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
D-Histidine SCHEMBL902054 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL4294462 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL27440707 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL305856 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL16714200 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL4297918 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL27767215 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL18419548 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL4735217 0.99 GSR (0.53) GSRITGB3ITGA2BARG1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675814-A1 COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES Bläss, Markus (DE) 2020-07-08 EP claimed
CN-109568594-A Polycation macromolecular prodrug is used for the preparation and application of gene delivery, nano composite system 南华大学 2019-04-05 CN claimed
US-20190025316-A1 PROTEIN INTERACTOR DETECTION SYSTEMS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-01-24 US claimed
US-9951183-B2 Amphiphilic blockcopolymers comprising reduction sensitive biodegradable polyesteramides DSM IP ASSETS, B.V. (NL) 2018-04-24 US claimed
US-20170218123-A1 AMPHIPHILIC BLOCKCOPOLYMERS COMPRISING REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES DSM IP ASSETS, B.V. (NL) 2017-08-03 US claimed
WO-2017123800-A1 PROTEIN INTERACTOR DETECTION SYSTEMS THE REGENTS OF UNIVERSITY OF CALIFORNIA (US) 2017-07-20 WO claimed
CN-105960411-A Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing 新加坡科技研究局 2016-09-21 CN claimed
CN-101812177-B Preparations of cationic polymer modified by steroid hormone and gene composite thereof UNIV CHINA PHARMA 2012-01-25 CN claimed
US-20030215877-A1 Directed protein docking algorithm CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-11-20 US claimed
WO-2003087310-A2 DIRECTED PROTEIN DOCKING ALGORITHM CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-10-23 WO claimed
CN-1193278-A Chemical compounds ZENECA LTD (GB) 1998-09-16 CN claimed
CN-118286454-A Lipid polypeptide nano delivery system with core-shell structure 圣诺生物医药技术(苏州)有限公司 2024-07-05 CN disclosed
US-12006500-B2 Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV) SIRNAOMICS, INC. (US) 2024-06-11 US disclosed
US-20240158794-A1 NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES SIRNAOMICS, INC. 2024-05-16 US disclosed
CN-114671912-B Method for homogeneously synthesizing blue copper tripeptide with assistance of light shearing carrier 西北工业大学 2024-05-14 CN disclosed
WO-1998024907-A1 NOVEL PROTEIN WITH CHEMOKINE ACTIVITY AMGEN INC. (US) 1998-06-11 WO disclosed
WO-1998016644-A1 FIBROBLAST GROWTH FACTOR HOMOLOGS ZYMOGENETICS, INC. (US) 1998-04-23 WO disclosed
WO-1998009991-A2 ENTERIC NEURAL PEPTIDE ZYMOGENETICS, INC. (US) 1998-03-12 WO disclosed
WO-1997043412-A1 NOVEL AGOUTI-RELATED GENE AMGEN INC. (US) 1997-11-20 WO disclosed
CN-1042821-A The production method of paddy plumule nutritious drink goods SHANGHAI INST OF CEREAL SCIENC (CN) 1990-06-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158794-A1 NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES ADAR, SAMHD1, RNASE1 GSR 2578/4885ITGB3 2204/4885ITGA2B 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.